Donepezil is a reversible acetylcholinesterase inhibitor classified as an anticholinesterase agent, primarily indicated for the symptomatic treatment of dementia associated with Alzheimer's disease. By… Read more




















Donepezil is a reversible acetylcholinesterase inhibitor classified as an anticholinesterase agent, primarily indicated for the symptomatic treatment of dementia associated with Alzheimer's disease. By inhibiting the hydrolysis of acetylcholine in the synaptic cleft, this medication enhances cholinergic transmission to improve cognitive function and behavioral symptoms. This category includes a comprehensive range of pharmaceutical reference standards, including the parent drug, its pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope labelled compounds. Pharmaceutical laboratories utilize these materials for critical analytical processes, including method validation, impurity profiling, and stability testing. By providing structurally characterized standards, these compounds support rigorous quality control and toxicological evaluation, ensuring that analytical methods remain accurate and reliable for the identification and quantification of related substances during the lifecycle of the drug product.